Daniel W. Wright
Oxford, ENG OX37DQ, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications
Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response.
Journal: Vaccines
Published: April 13, 2026
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Journal: Mayo Clinic proceedings. Innovations, quality & outcomes
Published: July 21, 2025
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.
Journal: The Lancet. Infectious diseases
Published: July 08, 2025
Pre-COVID-19 ex vivo cross-reactive IFN-γ cellular response to SARS-CoV-2 spike overlapping peptides is more prevalent among Kenyan compared to Swedish adults.
Journal: BMC infectious diseases
Published: March 19, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
Journal: The Journal of infection
Published: March 11, 2025
Rift Valley fever seroprevalence and risk factors among human populations in Uganda's cattle corridor: a cross-sectional study.
Journal: BMJ public health
Published: January 02, 2025
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.
Journal: Frontiers in immunology
Published: February 17, 2024
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Journal: Wellcome open research
Published: November 22, 2023
Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.
Journal: PLoS pathogens
Published: November 15, 2023
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
Journal: The Lancet. Infectious diseases
Published: November 12, 2023
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Journal: The Lancet. Microbe
Published: October 05, 2023
Last Updated: 09/26/2026